Leonard Dragone

Director Técnico/Científico/I+D en Abata Therapeutics, Inc. .

Health Technology

Consumer Services

Perfil

Leonard Dragone is currently the Chief Medical Officer at Abata Therapeutics, Inc. He holds a doctorate degree from The University of California, San Francisco.

Cargos activos de Leonard Dragone

Empresas	Cargo	Inicio
Abata Therapeutics, Inc. Abata Therapeutics, Inc. BiotechnologyHealth Technology Abata Therapeutics, Inc. is a biotech company based in Watertown, MA. Abata Therapeutics is focused on developing engineered Treg cell therapies for severe autoimmune and inflammatory diseases. The American company's lead programs are in ind-enabling studies for progressive multiple sclerosis and type 1 diabetes, both of which are tissue-specific autoimmune diseases with significant unmet needs. The company has developed a differentiated product engine to create tissue-specific, robust, and durable therapies. Abata Therapeutics was launched by Third Rock Ventures, with participation from a diverse syndicate of investors, including ElevateBio, Lightspeed Venture Partners, Invus, Samsara Biocapital, and the JDRF T1D Fund. The company was founded in 2021 by Richard Ransohoff and the CEO is Samantha Singer.	Director Técnico/Científico/I+D	20/04/2023

Todos los cargos activos de Leonard Dragone

Formación de Leonard Dragone.

The University of California, San Francisco

Doctorate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Leonard Dragone.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	1
Abata Therapeutics, Inc. Abata Therapeutics, Inc. BiotechnologyHealth Technology Abata Therapeutics, Inc. is a biotech company based in Watertown, MA. Abata Therapeutics is focused on developing engineered Treg cell therapies for severe autoimmune and inflammatory diseases. The American company's lead programs are in ind-enabling studies for progressive multiple sclerosis and type 1 diabetes, both of which are tissue-specific autoimmune diseases with significant unmet needs. The company has developed a differentiated product engine to create tissue-specific, robust, and durable therapies. Abata Therapeutics was launched by Third Rock Ventures, with participation from a diverse syndicate of investors, including ElevateBio, Lightspeed Venture Partners, Invus, Samsara Biocapital, and the JDRF T1D Fund. The company was founded in 2021 by Richard Ransohoff and the CEO is Samantha Singer.	Health Technology